Bausch + Lomb Presents New Scientific and Clinical Research During the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, CO

BRIDGEWATER, NJ — Bausch + Lomb, a leading global eye health company, will present numerous scientific posters during the Association for Research in Vision and Ophthalmology (ARVO) Annual meeting in Denver, CO (May 3-7). The presentations will showcase the results of various research studies from the company’s current product offerings and pipeline programs in pharmaceuticals, contact lenses and lens care, in addition to other subjects of interest. 

 “Bausch + Lomb is committed to identifying and exploring new treatment options and solutions for our customers and patients around the world,” said Ari Kellen, M.D., Head of U.S. Eye Health, Bausch + Lomb. “With our expanded investment in research and development, we continue each day to identify new potential offerings that will have the most meaningful impact in support of the eye health industry. We are proud to showcase our new research findings and look forward to communicating and collaborating with the eye care community during the annual ARVO meeting.” 

The research supported by Bausch + Lomb covers a variety of therapeutic areas, including outcomes from the following new research: 

• Preliminary 2014 results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study, which monitors the in vitro potency of a variety of common antibiotics against ocular pathogens collected nationwide
• An assessment of the real world experience using loteprednol etabonate ophthalmic gel, 0.5% (LOTEMAX® gel) for postoperative pain and inflammation following laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) surgery;
• A study of the efficacy and safety of investigational product brimonidine tartrate ophthalmic solution 0.025% used four times daily in a population of adult and geriatric subjects with ocular redness;
• An evaluation of the effect of lens wear on coefficient of friction (CoF) as compared to unworn daily disposable contact lenses;
• An assessment on the attraction of hyaluronate (HA), present in Biotrue® Multi-Purpose Solution, to the surface of samfilcon A, senofilcon A, and comfilcon A silicone hydrogels (SiHy);
• A comparison of the efficacy of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (Zylet®) and dexamethasone 0.1%/tobramycin 0.3% ophthalmic suspension (Tobradex) in reducing signs of blepharitis.

The following schedule includes the Bausch + Lomb-supported poster presentations that will be featured during the ARVO annual meeting:

“Antibiotic Resistance Among Ocular Pathogens – Results from the ARMOR Surveillance Study 2013- Present.” Asbell, Penny A.; Sanfilippo, Christine M.; Sahm, Daniel F.; DeCory, Heleen H. [Sunday, May 3, 8:30 – 10:15 a.m. PT, Session 111, Poster 284 – C0169].

“A single-center, double-masked, randomized, vehicle-controlled, parallel-group study evaluating the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% used four times daily in a population of adult and geriatric subjects with ocular redness.” Scassellati-Sforzolini, Baldo; Ngumah, Quintus; Gomes, Paul J. [Sunday, May 3, 1:30 – 3:15 p.m. PT, Session 142, Poster 699 - C0147].

“Viscoelastic and dissolution characterization of submicron loteprednol etabonate ophthalmic gel, 0.38%.” Phillips, Eric; Coffey, Martin J.; Shawer, Mohannad. [Monday, May 4, 8:30 to 10:15 a.m. PT, Session 224, Poster 1525 - C0133].

“Ocular pharmacokinetics of submicron loteprednol etabonate ophthalmic gel, 0.38% following topical administration in rabbits.” Cavet, Megan E.; Glogowski, Shellise; DiSalvo, Christopher; Richardson, Mary E. [Monday, May 4, 8:30 to 10:15 a.m. PT, Session 224, Poster 1524 - C0132].

“Retrospective Assessment of the Routine Use of Loteprednol Etabonate Gel 0.5% Following LASIK and PRK Surgery.” Salinger, Clifford; Gordon, Michael; Jackson, Mitchell; Donnenfeld, Eric D. [Tuesday, May 6, 3:45 – 5:30 p.m. PT, Session 383, Poster 3932 – D0137].

“A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Pediatric, Adult, and Geriatric Subjects.” Ngumah, Quintus; Scassellati-Sforzolini, Baldo; Gomes, Paul J. [Wednesday, May 6, 3:45 – 5:30 p.m. PT, Session 468, Poster 4866 – A0019].

“Zylet® (loteprednol etabonate 0.5%/tobramycin 0.3%) Compared with Tobradex (dexamethasone

0.1%/tobramycin 0.3%) for the treatment of blepharitis in a large international population.” Comstock, Timothy; DeCory, Heleen H. [Wednesday May 6, 3:45 – 5:30 p.m. PT, Session 468, Poster 4867 – A0020].

“Coefficient of Friction Analysis of Unworn and Worn Daily Disposable Contact Lenses.” Schafer, Jeffery; Hook, Daniel; Lusignan, Charles; and Steffen, Robert B. [Thursday, May 7, 12:00 – 1:45 p.m. PT, Session 541, Poster 6110 – C0045].

“Characterization of Bulk PVP Content of samfilcon A Silicone Hydrogel Lenses.” Hoteling, Andrew; Nichols, William; Harmon, Patricia; Conlon, Shawn; Hook, Daniel; Nuñez, Ivan; Hoff, Joseph; and Cabarcos, Orlando. [Thursday, May 7, 12:00 – 1:45 p.m. PT, Session 541, Poster 6095 – C0030].

“Physico-chemical Evidence for A Confluent Hyaluronate Network on the Surface of Silicone Hydrogel Lens Materials.” Wygladacz, Katarzyna A.; and Hook, Daniel. [Thursday, May 7, 12:00 – 1:45 p.m. PT,, Session 541, Poster 6097 – C0032].

LOTEMAX® GEL INDICATION:

LOTEMAX® GEL (loteprednol etabonate ophthalmic gel) 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.

IMPORTANT SAFETY INFORMATION:

LOTEMAX® GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.

Use of corticosteroids may result in posterior subcapsular cataract formation.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, and where appropriate, fluorescein staining.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infections.

Use of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.

Patients should not wear contact lenses when using LOTEMAX® GEL.

The most common ocular adverse drug reactions were anterior chamber inflammation (5%), eye pain (2%) and foreign body sensation (2%).

Please click here for Prescribing Information for LOTEMAX® GEL .

ZYLET® INDICATION AND USAGE:

ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae,Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

IMPORTANT SAFETY INFORMATION:
 

• ZYLET® is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
• Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored.
• Use of corticosteroids may result in posterior subcapsular cataract formation.
• The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as a slit lamp biomicroscopy and, where appropriate, fluorescein staining.
• Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.
• Employment of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex).
• Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
• Most common adverse reactions reported in patients were injection and superficial punctate keratitis, increased intraocular pressure, burning and stinging upon instillation.

Please click here for Prescribing Information for ZYLET®.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries. 
 

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.

All other brand/product names are trademarks of their respective owners. 
© 2015 Bausch & Lomb Incorporated.

# # #

News Media Contacts
Kristy Marks

PR Product Manager, Bausch + Lomb

(585) 338-8095 or kristy.marks@bausch.com

Tad Heitmann
BioComm Network on behalf of Bausch + Lomb
(714) 273-2937 or theitmann@BioCommNetwork.com

US/LGX/15/0053